Siponimod enriches regulatory T and B lymphocytes in secondary progressive multiple sclerosis

BACKGROUND: Siponimod (BAF312) is a selective sphingosine-1-phosphate receptor 1 and 5 (S1PR1, S1PR5) modulator recently approved for active secondary progressive multiple sclerosis (SPMS). The immunomodulatory effects of siponimod in SPMS have not been previously described. METHODS: We conducted a...

Disgrifiad llawn

Wedi'i Gadw mewn:
Manylion Llyfryddiaeth
Cyhoeddwyd yn:JCI Insight
Prif Awduron: Wu, Qi, Mills, Elizabeth A., Wang, Qin, Dowling, Catherine A., Fisher, Caitlyn, Kirch, Britany, Lundy, Steven K., Fox, David A., Mao-Draayer, Yang
Fformat: Artigo
Iaith:Inglês
Cyhoeddwyd: American Society for Clinical Investigation 2020
Pynciau:
Clinical Medicine
Mynediad Ar-lein:https://ncbi.nlm.nih.gov/pmc/articles/PMC7098784/
https://ncbi.nlm.nih.gov/pubmed/31935197
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1172/jci.insight.134251
Tagiau: Ychwanegu Tag
Dim Tagiau, Byddwch y cyntaf i dagio'r cofnod hwn!

Eitemau Tebyg